The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001372370p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
5/10/2026
Date registered
Help: Date registered
16/11/2026
Date last updated
Help: Date last updated
16/11/2026
Date data sharing statement initially provided
Help: Data sharing statement date
16/11/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
LIGHTWELL-NT: A randomised, participant-blinded, sham-controlled trial of repeated whole body narrowband UVB (ultraviolet B) exposure on wellbeing and systemic physiology in healthy adults.
Scientific title
LIGHTWELL-NT: A randomised, participant-blinded, sham-controlled trial of repeated whole-body narrowband UVB exposure on wellbeing and systemic physiology in healthy adults.
Additional trial identifiers [1] 318574 0
Nil
Universal Trial Number (UTN)
Trial acronym
LIGHTWELL-NT
Related trial records

Health condition
Health condition(s) studied:
Fatigue 343778 0
Low stamina 344098 0
Condition category
Condition code
Mental Health 339903 339903 0 0
Studies of normal psychology, cognitive function and behaviour

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
150 healthy adults aged 18-80 years (with no pre-existent dermatological conditions), will be randomised to receive active narrowband ultraviolet B (NBUVB) phototherapy (wavelength range 311-312 nm). Run-in phase will apply to all participants and will be completed after being recruited but before commencing treatment sessions, with an estimated duration of 45 minutes (to counsel, complete consents, enrolling paperwork and baseline well-being questionnaires during a one-on-one session with one of the doctors/lead investigators). Intervention will take place at Darwin Dermatology, Suite 4, 5 Tiwi Gardens, Tiwi NT 0810 (single centre) using medical device Kernel KN-4005 whole-body NB-UVB phototherapy cabinet. Treatment will consist of 3 supervised sessions/week for 8 weeks (target 24 sessions). The regimen intentionally uses a conservative systemic-exposure schedule rather than high-dose disease treatment. It is based on the published 24-session/8-week PhoCIS systemic NB-UVB regimen, which begins at 20 mJ/cm2 and escalates slowly by 10% of the dose each session, following a nominal dose schedule according to participants skin phototype. Reminders prior to each session will be sent to participants. Each session is monitored by doctors on site, and/or nurses on site and/or specialised clinical trial staff. Clinical monitoring will be done at baseline, 4 weeks, 8 weeks and 12 weeks. Biomarker assessments (bloods and stool samples) are not considered outcomes for the current study, however, they are included on the master protocol, study design and participant information sheet as EXPLORATORY OUTCOMES to be measured at baseline and repeat at 12 weeks for electronic/clinical follow-up.
Intervention code [1] 335481 0
Treatment: Devices
Intervention code [2] 335482 0
Lifestyle
Description of the comparator or control
150 healthy adults aged 18-80 years (with no pre-existent dermatological conditions), will be randomised to receive a technically validated SHAM narrowband ultraviolet B (NBUVB) phototherapy that preserves cabinet ritual/visible cues but blocks therapeutic UVB . Run-in phase will apply to all participants and will be completed after being recruited but before commencing treatment sessions, with an estimated duration of 45 minutes (to counsel, complete consents, enrolling paperwork and baseline well-being questionnaires during a one-on-one session with one of the doctors/lead investigators). Intervention will take place at Darwin Dermatology, Suite 4, 5 Tiwi Gardens, Tiwi NT 0810 (single centre) using medical device Kernel KN-4005 whole-body NB-UVB phototherapy cabinet in which, medical phototherapy light tubes have been replaced for decorative LED tubes custom manufactured to preserves cabinet ritual/visible cues. Treatment will consist of 3 supervised sessions/week for 8 weeks (target 24 sessions). The regimen intentionally uses a conservative systemic-exposure schedule rather than high-dose disease treatment. It is based on the published 24-session/8-week PhoCIS systemic NB-UVB regimen, which begins at 20 mJ/cm2 (sham in this case) and escalates slowly by 10% of the dose each session, following a nominal dose schedule according to participants skin phototype. Reminders prior to each session will be sent to participants. Each session is monitored by doctors on site, and/or nurses on site and/or specialised clinical trial staff. Clinical monitoring will be done at baseline, 4 weeks, 8 weeks and 12 weeks. Biomarker assessments (bloods and stool samples) are not considered outcomes for the current study, however, they are included on the master protocol, study design and participant information sheet as EXPLORATORY OUTCOMES to be measured at baseline and repeat at 12 weeks for electronic/clinical follow-up.
Control group
Placebo

Outcomes
Primary outcome [1] 347087 0
Subjective psychological well-being over the last two weeks
Timepoint [1] 347087 0
- Baseline (day of run-in and randomisation session): 1-2 weeks after screening/recruitment. - Questionnaire will repeated at following timepoints after commencing intervention sessions: 2 weeks, 4 weeks, 6 weeks, 8 weeks and 12 weeks.
Secondary outcome [1] 468871 0
Feelings of energy, aliveness, and eudaimonic well-being.
Timepoint [1] 468871 0
- Baseline (day of run-in and randomisation session): 1-2 weeks after screening/recruitment. - Questionnaire will repeated at following timepoints after commencing intervention sessions: 2 weeks, 4 weeks, 6 weeks, 8 weeks and 12 weeks.
Secondary outcome [2] 468872 0
Frequency and impact of fatigue over the past 7 days, graded on a 5-point scale from 1 ("Not at all") to 5 ("Very much").
Timepoint [2] 468872 0
- Baseline (day of run-in and randomisation session): 1-2 weeks after screening/recruitment. - Questionnaire will repeated at following timepoints after commencing intervention sessions: 2 weeks, 4 weeks, 6 weeks, 8 weeks and 12 weeks.
Secondary outcome [3] 468873 0
Sleep quality, sleep problems, and difficulties falling or staying asleep over the past 7 days
Timepoint [3] 468873 0
- Baseline (day of run-in and randomisation session): 1-2 weeks after screening/recruitment. - Questionnaire will repeated at following timepoints after commencing intervention sessions: 2 weeks, 4 weeks, 6 weeks, 8 weeks and 12 weeks.
Secondary outcome [4] 468874 0
Person's perceived capacity to carry out everyday family, work, school, and leisure roles
Timepoint [4] 468874 0
- Baseline (day of run-in and randomisation session): 1-2 weeks after screening/recruitment. - Questionnaire will repeated at following timepoints after commencing intervention sessions: 2 weeks, 4 weeks, 6 weeks, 8 weeks and 12 weeks.

Eligibility
Key inclusion criteria
1. Age 18-80 years inclusive.
2.Able to provide informed consent and comply with three site visits per week for 8 weeks.
3. Self-reported generally good health, with no unstable medical condition likely to materially affect participation or wellbeing over the study period.
4. Two pre-randomisation WHO-5 assessments (screening and baseline/run-in completion) each between 40 and 80 inclusive on the 0-100 scale.
5. PHQ-9 < 10 at screening and no endorsement of suicidal ideation requiring clinical review.
6. No active psychiatric disorder requiring current treatment and no current bipolar/psychotic disorder.
7. Fitzpatrick skin phototype I-VI, assessed by trained study staff.
8. Able to complete the study questionnaires in validated English versions, unless an approved validated translation is implemented.
9. Willing to maintain usual sun-protection/outdoor behaviour and avoid tanning beds, deliberate tanning programs and other medical UV phototherapy during the intervention.
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
- Active dermatologic disease that itself requires phototherapy or is expected to materially improve with NB-UVB and thereby confound wellbeing.
- Known photosensitivity disorder (including lupus photosensitivity, porphyria, xeroderma pigmentosum or equivalent high-risk condition).
- History of melanoma, unusually high skin-cancer risk in the investigator’s judgement, or prior UV treatment burden making further elective exposure inappropriate.
- Current clinically important photosensitising medication or inability to avoid a medication judged incompatible with study exposure; medically required treatments must never be stopped solely to enter the study.
- NB-UVB/PUVA/tanning-bed use within the preceding 3 months.
- Planned intensive sun holiday or prolonged travel expected to make environmental exposure or attendance non-comparable.
- Pregnancy or breastfeeding. A urine pregnancy test is performed at baseline and week 4 for participants with pregnancy potential unless documented not applicable.
- PHQ-9 >10, active suicidal ideation, recent self-harm, psychosis, unstable major psychiatric illness, or other circumstance requiring treatment rather than research participation.
- Clinically unstable cardiovascular disease, uncontrolled hypertension or other condition judged by a study doctor to make participation unsafe.
- Any condition, life circumstance or likely adherence problem that the investigator judges would prevent valid or safe participation.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
central randomisation.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
computer-generated random sequence.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
1. Analysis populations
- Intention-to-treat (primary): all randomised participants analysed by allocated arm.
- Per-protocol supportive: participants receiving greater than or equal to 20 of 24 sessions, with no major treatment-separation deviation and a week-8 outcome.
- Safety: all participants who enter a treatment cabinet at least once, analysed by exposure received for safety descriptions.
2. Primary analysis: ANCOVA of week-8 WHO-5 with treatment arm as the effect of interest, adjusted for the mean of the two pre-randomisation WHO-5 scores and randomisation stratification variables. Report adjusted mean difference, 95% CI and two-sided p value. Alpha=0.05. A repeated-measures mixed model using weeks 2/4/6/8/12 is supportive, not a substitute for the pre-specified primary analysis.
3. Key secondary multiplicity: Conditional on completion of the primary analysis, the four key clinical secondary outcomes (SVS, PROMIS fatigue, PROMIS sleep disturbance, PROMIS social roles) form a Holm-adjusted family at week 8. Serum 25(OH)D is reported as
target engagement with effect size and CI and is not used to make a broad wellbeing efficacy claim.
4. Exploratory analyses: Other PROMIS domains, cognition, CSI-4, SexFS, weekly discovery items, gastrointestinal/bowel outcomes, Blood Pressure/Heart Rare and serum/stool biomarkers are exploratory. Biomarker assessments (bloods and stool samples) are not considered outcomes for the current study, however, they are included on the master protocol, study design and participant information sheet as EXPLORATORY OUTCOMES. For this reason, they have not been included on primary and secondary outcomes section of this application. See list below for further details:
a. Nitric oxide pathway (serum): Plasma nitrite (NO2), Plasma nitrate (NO3), Nitrite/nitrate ratio and Nitrosothiols (RS-NO).
b. Inflammatory / immune biomarkers (serum): Interleukin-6 (IL-6), Tumour necrosis factor-alpha (TNF-a), Interleukin-10 (IL-10).
c. Neuroendocrine / wellbeing biomarkers (serum): Brain-derived neurotrophic factor (BDNF), ß-Endorphin.
d. Other exploratory (non-blood) biomarkers: stool microbiome (16S rRNA sequencing).

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NT
Recruitment postcode(s) [1] 46734 0
0810 - Tiwi

Funding & Sponsors
Funding source category [1] 323152 0
Commercial sector/Industry
Name [1] 323152 0
Darwin Dermatology & Ologist (private practice)
Country [1] 323152 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
DEVTIL PTY LTD
Address
Country
Australia
Secondary sponsor category [1] 326112 0
Individual
Name [1] 326112 0
Dr Dev Tilakaratne (Consultant Dermatologist) - Darwin Dermatology & Ologist (private practice)
Address [1] 326112 0
Country [1] 326112 0
Australia

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 321557 0
Human Research Ethics Committee of the Northern Territory Department of Health and Menzies School of Health Research
Ethics committee address [1] 321557 0
Ethics committee country [1] 321557 0
Australia
Date submitted for ethics approval [1] 321557 0
07/10/2026
Approval date [1] 321557 0
Ethics approval number [1] 321557 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 154062 0
Dr Dev Tilakaratne
Address 154062 0
Darwin Dermatology, Unit 4/5 Tiwi Gardens, Tiwi NT 0810
Country 154062 0
Australia
Phone 154062 0
+61 402 766 109
Fax 154062 0
Email 154062 0
Contact person for public queries
Name 154063 0
Dev Tilakaratne
Address 154063 0
Darwin Dermatology, Unit 4/5 Tiwi Gardens, Tiwi NT 0810
Country 154063 0
Australia
Phone 154063 0
+61 402 766 109
Fax 154063 0
Email 154063 0
Contact person for scientific queries
Name 154064 0
Dev Tilakaratne
Address 154064 0
Darwin Dermatology, Unit 4/5 Tiwi Gardens, Tiwi NT 0810
Country 154064 0
Australia
Phone 154064 0
+61 402 766 109
Fax 154064 0
Email 154064 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.